What happened with SYK today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Stryker supplies the tools healthcare teams use to perform surgery, treat patients and provide hospital care. Most revenue comes from its MedSurg and Neurotechnology business, which sells products such as surgical and endoscopic equipment, patient-handling equipment and devices used to treat strokes. Orthopaedics is the other substantial business, supplying implants for joint replacements and treatment of fractures and other injuries. Its Mako SmartRobotics technology supports hip and knee replacement procedures.
The company sells directly to doctors, hospitals and other healthcare facilities, as well as through independent dealers and distributors. It operates globally, but the United States accounts for most sales. Healthcare providers’ purchasing decisions turn demand for these procedures and hospital services into orders for Stryker’s products.
Demand depends partly on the number of procedures performed, including elective surgery. Insurance coverage and reimbursement influence which products providers choose and the prices they will pay. Stryker must also obtain and maintain required regulatory clearances or approvals and comply with rules governing manufacturing and sales; these requirements limit which products it can bring to market.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Stryker’s results hinge on demand for orthopedic and hospital procedures, with privately held Arthrex and overseas-listed Olympus also worth watching as rivals in sports medicine and endoscopy, respectively.
Zimmer Biomet competes directly with Stryker for orthopedic surgeons’ and hospitals’ purchases of joint-replacement implants, extremity products and surgical robots. Its knee and hip results and new robotic technologies are the clearest areas to watch for competitive pressure on Stryker.
Smith+Nephew challenges Stryker in hip and knee implants, trauma and extremity products, surgical robotics and sports medicine sold to healthcare systems. Its hip and knee implant business offers a focused comparison for Stryker’s joint-replacement results, while sports medicine adds another competitive front.
Medtronic competes with Stryker for healthcare providers’ purchases of surgical instruments and devices for vascular and cranial procedures. New products in those areas matter more to this comparison than Medtronic’s diabetes pumps and glucose-monitoring business.
Johnson & Johnson’s MedTech business challenges Stryker in joint replacements, trauma implants, surgical instruments and neurovascular devices used by healthcare providers. Those device businesses—not Johnson & Johnson’s prescription medicines—are the relevant comparison for Stryker.
CONMED Corporation competes with Stryker for surgical-device purchases through powered instruments, orthopedic sports-medicine products and endoscopic equipment. Its orthopedic and general-surgery sales provide two separate views of the markets where Stryker faces it.
Penumbra competes with Stryker, including its Inari business, in devices clinicians use to remove clots, treat strokes and block blood vessels—thrombectomy and embolization. Its thrombectomy sales are the line to watch for competition in Stryker’s vascular business.
Baxter competes with Stryker for hospitals’ purchases of beds, connected-care technologies and surgical products. Its smart beds and tools that connect care teams are the offerings to watch alongside Stryker’s patient-handling and clinical-communication products.
Integra LifeSciences competes with Stryker in technologies and specialty instruments used in brain surgery through Codman Specialty Surgical. That business accounts for roughly 70% of Integra’s revenue, making its neurosurgery results more relevant to Stryker than its Tissue Technologies business.
Enovis Corporation’s Reconstructive business competes with Stryker by supplying implants and surgical tools for joint replacement, limb reconstruction and foot-and-ankle procedures. Watch that business’s results rather than its non-surgical bracing and rehabilitation products.
STERIS competes with Stryker for hospitals’ purchases of procedural equipment, instruments and endoscopy products. STERIS says more procedures, including preventive endoscopies and colonoscopies, support demand for many of its offerings, making that demand useful context for Stryker’s endoscopy business.
Boston Scientific competes with Stryker in devices used for peripheral vascular procedures, including removing blood clots.
Medline Inc.’s own-brand medical-surgical products compete with Stryker’s Medical offerings for purchases by hospitals and other healthcare facilities. Its Medline Brand sales are the relevant comparison, rather than sales of other manufacturers’ products through its supply-chain business.
Globus Medical competes with Stryker in musculoskeletal implants and systems that guide and robotically assist surgery, but their overlap is narrowing as Stryker’s spinal implant business shrinks. Stryker’s spinal implant sales fell 73.9% in 2025, so Globus’s navigation and robotics developments remain a more useful area to watch.
Stryker pays UFP Technologies Inc to manufacture custom medical devices and components, so this supplier depends materially on Stryker’s orders. Stryker accounted for 21.5% of UFP’s 2025 sales, making sales to that customer the clearest line to watch.
Treace Medical Concepts, Inc. challenges Stryker with implants and instruments for bunion correction in the foot-and-ankle market, where Treace identifies Stryker as the leader. New bunion-correction systems are the specific competitive developments to watch against Stryker’s extremity products.
AngioDynamics, Inc. competes with Stryker by selling clinicians systems that remove blood clots to treat venous thromboembolism. Developments in its AngioVac and AlphaVac clot-removal systems are the products to watch for competition with Stryker’s vascular offerings.
Integra LifeSciences Holdings earningsIART
Integra LifeSciences’ report will show how hospitals are buying brain-surgery technologies and specialty instruments, markets where it competes directly with Stryker’s Neuro Cranial business.
Focus on Integra’s Codman Specialty Surgical business, not Tissue Technologies. Growth there would indicate supported demand for brain-surgery products, a favorable market signal for Stryker’s Neuro Cranial business; weak sales would point to softer demand or tougher competition.
CONMED Corporation earningsCNMD
CONMED’s report will show hospital purchasing of powered surgical instruments and endoscopic equipment, markets where it competes with Stryker’s MedSurg products.
Separate CONMED’s orthopedic sales from its general-surgery sales: the former includes orthopedic sports-medicine products, while the latter includes powered instruments and endoscopic equipment. Growth in the relevant sales would show continued hospital purchasing and support demand for Stryker’s MedSurg products; declines would point to weaker purchasing or tougher competition.
Fed Interest Rate Decision
The Fed’s rate decision signals the direction of borrowing costs across the economy, which can change what Stryker pays to borrow or refinance its $15.9 billion of debt.
Expected4.0%Last release4.0%
If it comes in above expectations
If the policy rate is higher than expected, Stryker could face higher costs on debt that reprices and on new borrowing or refinancing, leaving less cash for operating needs and other uses.
If it comes in below expectations
If the policy rate is lower than expected, Stryker could face lower costs on debt that reprices and on new borrowing or refinancing, leaving more cash for operating needs and other uses.
Stryker Corporation earningsThis company
Stryker’s report will show whether hospitals and clinicians are buying more across both of its businesses, and whether those sales support its gross margin.
Read sales growth in MedSurg and Neurotechnology alongside Orthopaedics, then compare both with gross margin. More shipments across both segments with a steady or higher margin would show broad purchasing and that Stryker is retaining its share of sales after product costs. Growth concentrated in one segment, or more shipments alongside a weaker margin, would point to narrower demand or costs and pricing squeezing the return on sales.
UFP Technologies Inc earningsUFPT
UFP Technologies’ report will show how important orders from Stryker are to this supplier of custom medical devices and components.
Look for UFP’s sales to Stryker or their share of UFP’s revenue. An increase would show that Stryker is bringing this supplier more business; a decline would indicate fewer related orders or a smaller share of UFP’s business. UFP is only one supplier, so this figure alone cannot establish Stryker’s total purchasing or product demand.
Penumbra, Inc. earningsPEN
Penumbra’s report will show how clinicians are buying thrombectomy devices, a market where it competes with Stryker’s Inari business.
Focus on Penumbra’s thrombectomy sales, not its entire business. Growth would show clinicians buying more in this shared market, a demand signal for Stryker’s Vascular business; a decline could mean weaker demand or more competitive pressure, but does not establish how Stryker itself sold.
STERIS plc earningsSTE
STERIS’s report will show how demand for related procedures and endoscopy equipment is changing, providing context for Stryker’s Endoscopy business.
Read STERIS’s comments on procedure volumes and endoscopy demand alongside sales of its procedural and endoscopy products. Stronger demand and sales would indicate a supportive purchasing backdrop for Stryker’s Endoscopy business; weakness would mean less support, though STERIS’s results do not directly establish Stryker’s sales.
Zimmer Biomet Holdings, Inc. earningsZBH
Zimmer Biomet’s report will show hospital and surgeon purchasing of joint-replacement implants and extremity products, markets where it competes directly with Stryker.
Focus on Zimmer Biomet’s knee, hip and extremity sales, and watch for developments in its robotic technologies. Growth in those sales would show more purchasing in shared markets; weak sales or stronger competition from new technologies could put pressure on Stryker’s knee, hip and extremity products.
